Zhonghua wai ke za zhi [Chinese journal of surgery] · 1998
[Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wen R, Zhou G, Xie S, Lian B, Sun X, Chen J
Аннотация
OBJECTIVE: To study the mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2.
METHOD: Intravesical instillation of BCG or BCG plus IL-2 were carried out in the bladder transitional cell carcinoma patients undergoing surgical operation (16, 19 cases respectively).
RESULT: They were followed up for 14-22 months. The recurrence rates were 31.25% and 21.05% respectively. At 6 weeks after the instillation of IL-2 plus BCG, the peripheral blood NKCF activity was increased significantly and there was a significant positive correlation between the activities of NKCF and IL-2.
CONCLUSION: The intravesical instillation of IL-2 plus BCG is clearly superior to only BCG in preventing recurrence of bladder carcinoma. There may be immuno-enhancement and immuno-synergism.
METHOD: Intravesical instillation of BCG or BCG plus IL-2 were carried out in the bladder transitional cell carcinoma patients undergoing surgical operation (16, 19 cases respectively).
RESULT: They were followed up for 14-22 months. The recurrence rates were 31.25% and 21.05% respectively. At 6 weeks after the instillation of IL-2 plus BCG, the peripheral blood NKCF activity was increased significantly and there was a significant positive correlation between the activities of NKCF and IL-2.
CONCLUSION: The intravesical instillation of IL-2 plus BCG is clearly superior to only BCG in preventing recurrence of bladder carcinoma. There may be immuno-enhancement and immuno-synergism.